DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Gadoxetic acid
Gadoxetic acid
List of Union Reference Dates A
Gadolinium Based Contrast Agents
Advisory Committee Briefing Document Medical Imaging Drugs Advisory Committee (MIDAC) September 8, 2017
Estonian Statistics on Medicines 2016 1/41
Injection of Contrast Media V7 – 2010 13 5
Art. 31 Gadolinium
Public Assessment Report for Paediatric Studies Submitted in Accordance with Article 46 of Regulation (EC) No1901/2006, As Amended
Active Moiety Name FDA Established Pharmacologic Class (EPC) Text
PART VI Summary of Activities in the Risk Management Plan by Product
Application for Inclusion of Gadolinium-Based Contrast Agents to the WHO
Estonian Statistics on Medicines 2013 1/44
Environmentally Classified Pharmaceuticals 2014-2015
Use of Cardiotrophin-1 for the Treatment of Kidney Diseases
DTPA-Enhanced MRI ⇑ Laura Fernandez-De-Manuel A,B, , Gert Wollny A,B, Jan Kybic C, Daniel Jimenez-Carretero A,B, Jose M
Chapter 138A Pharmacy and Poison Regulations.Pdf
FDA Listing of Established Pharmacologic Class Text Phrases January 2021
Stembook 2018.Pdf
Diagnostic Performance of Gadoxetic Acid
Top View
(12) Patent Application Publication (10) Pub. No.: US 2016/0348103 A1 WHEELER Et Al
Gadolinium Containing Contrast Agents
Gadoxetic Acid (Rinn) Preparations Acide Gadoxétique; Ácido Gadoxético; Acidum Gadoxeticum; Pharmacopoeias
Manual on Contrast Media Version 7 2010
WO 2017/222911 A1 (.Pdf)
Diagnostic Accuracy of Gadoxetic Acid-Enhanced MR for Small Hypervascular Hepatocellular Carcinoma and the Concordance Rate of Liver Imaging Reporting and Data System (LI-RADS)
Biem Pharmaceuticals Is
Provisional Peer-Reviewed Toxicity Values for Stable (Nonradioactive) Gadolinium (Casrn 7440-54-2) and Soluble Salts
Atc Index 2010
WO 2014/153118 Al 25 September 2014 (25.09.2014) P O P C T
Comprehensive Contrast Policy Page 2 of 25
Gadoxetic Acid–Enhanced Magnetic Resonance Imaging and Contrast
Pharmacologyonline 3: 728-781 (2010) Newsletter Bradu and Rossini
Superparamagnetic Iron Oxide Nanoparticles in Biomedicine
Safety and Clinical Usefulness of Gadoteric Acid Including Post-Marketing Surveillance
Harmonized Tariff Schedule of the United States (2006) (Rev
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Smart MRI Agents for Detecting Extracellular Events in Vivo: Progress and Challenges
Pharmacokinetics Uses and Administration Adverse Effects And
Assessment Report
Pharmaceutical Appendix to the Tariff Schedule 2
4,436 Reports from Italy, Accepted in the Who Upm
Medicines Adverse Reactions Committee
Application for Inclusion of Gadoterate Meglumine Pdf, 853Kb
Gadolinium-Containing Contrast Agents
Resolution Ap (2000) 1
Gd-EOB-DTPA) in Contrast-Enhanced MRI for the Diagnosis of Hepatocellular Carcinoma